Locations and Physicians

Govardhanan Nagaiah MD, MS

Patient Portal Genetic Testing


Medical Oncology & Hematology


Glendale - Saguaro Cancer Center
7200 W. Bell Road, Building A
Glendale, AZ 85308
Phone: (623) 487-4822
Fax: (623) 334-9881

Goodyear - Medical Oncology & Hematology, Gynecologic Oncology
13555 W. McDowell Rd., Suite 206
Goodyear, AZ 85395
Phone: 623-469-4222
Fax: 623-535-7367

Govardhanan Nagaiah, MD, MS

Medical School

MGR Medical University,Chennai, India


Mercy Catholic Medical Center,Darby, (Philadelphia) PA


Mercy Catholic Medical Center, Darby, (Philadelphia) PA and National Health Service, United Kingdom


West Virginia University, Morgantown, WV

Board Certification

Dr. Nagaiah is board certified in medical oncology, hematology and internal medicine.




I believe that being an oncologist is a privilege that is not to be taken lightly. I strive to provide, evidence based care that is appropriate to my patients particular problem, recognizing and respecting individual patient’s wishes. I take a multidisciplinary approach to care including alternative therapies that have been shown to be effective.

Academic Honors & Professional Achievements

Masters in Clinical Research: MGH Institute of Health Professions, Boston


1. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.

2. Batalo M, Nagaiah G, Abraham J. Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. Expert Rev Anticancer Ther. 2011;11(8):1277-1282.

3. Nagaiah G, Remick SC. Combretastatin A4 phosphate: A novel vascular disrupting agent. Future Oncol. 2010;6(8):1219-1228

4. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233-240.

5. Nagaiah G, Almubarak M, Khan M, Altaha R. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: Report of two cases and review of literature. Cancer Invest. 2010;28(10):1048-1053